May 18th, 2022
From the desk of The Editor
Dear Reader,
We have identified several healthtech stocks which are expected to go “Ex-Dividend” starting today.
If you purchase a stock on its ex-dividend date or after, you will not receive the next dividend payment.
Instead, the seller gets the dividend. If you purchase before the ex-dividend date, you get the dividend.
If you sell your stock before the ex-dividend date, you also are selling away your right to the stock dividend.
So please keep this in mind.
Below is our latest Dividend Report:
Laboratory
Symbol: LH
Recent Price: $$247.03
Average Analyst Price Target: $312.20 (26.38%)
Market Cap: $$22.90B
Expected Ex-Dividend Date: May 18 2022
Expected Payment Date: Jun 09 2022
Expected Dividend & Yield: 0.30%
Recent Analyst Action: Eric Coldwell, analyst at Robert W. Baird, reiterates coverage on Laboratory (LH) in the Healthcare sector with a Buy rating and a price target of $ 325 (6 days ago).
TipRanks.com also reports that Laboratory currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $312.20 . The target pricing ranges from a high forecast of $350.00 down to a low forecast of $265.00. Laboratory (LH)’s last closing price was $$247.03 which would put the average price target at 26.38% upside.Here are 3rd party ratings for LH:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 14% (217 out of 253)
--------------------------------------------------------------------------
Select Medical
Symbol: SEM
Recent Price: $$25.18
Average Analyst Price Target: $35.67 (41.69%)
Market Cap: $$3.29B
Expected Ex-Dividend Date: May 18 2022
Expected Payment Date: Jun 01 2022
Expected Dividend & Yield: 1.94%
Recent Analyst Action: Nick Giovacchini, analyst at Credit Suisse, reiterates coverage on Select Medical (SEM) in the Healthcare sector with a Hold rating and a price target of $ 27 (1 day ago).
TipRanks.com also reports that Select Medical currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $35.67 . The target pricing ranges from a high forecast of $44.00 down to a low forecast of $27.00. Select Medical (SEM)’s last closing price was $$25.18 which would put the average price target at 41.69% upside.Here are 3rd party ratings for SEM:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 38% (96 out of 253)
--------------------------------------------------------------------------
Royalty Pharma
Symbol: RPRX
Recent Price: $$41.36
Average Analyst Price Target: $51.75 (25.12%)
Market Cap: $$18.00B
Expected Ex-Dividend Date: May 19 2022
Expected Payment Date: Jun 15 2022
Expected Dividend & Yield: 1.80%
Recent Analyst Action: Adam Buckham, analyst at Scotiabank, reiterates coverage on Royalty Pharma (RPRX) in the Healthcare sector with a Buy rating and a price target of $ 53 (5 days ago).
TipRanks.com also reports that Royalty Pharma currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $51.75 . The target pricing ranges from a high forecast of $56.00 down to a low forecast of $48.00. Royalty Pharma (RPRX)’s last closing price was $$41.36 which would put the average price target at 25.12% upside.Here are 3rd party ratings for RPRX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Sell, Bottom 43% (145 out of 253)
--------------------------------------------------------------------------
And there you have it...
Keep in mind, if you purchase a stock on its ex-dividend date or after, you will not receive the next dividend payment.
Instead, the seller gets the dividend. If you purchase before the ex-dividend date, you get the dividend.
If you sell your stock before the ex-dividend date, you also are selling away your right to the stock dividend.
If you have questions about specific dividends, you should consult with your financial advisor or visit Investor.gov for more information.
Sincerely,
The Editor
